These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29500843)

  • 1. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
    Tamura K; Kodaira M; Shimizu C; Yonemori K; Yunokawa M; Shimomura A; Kobayashi T; Nakano K; Tomomatsu J; Ito Y; Tanaka J; Kuriki H; Gu Z; Takahashi S
    Cancer Sci; 2018 May; 109(5):1592-1601. PubMed ID: 29500843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
    Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
    Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
    Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
    Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
    Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.
    Moein A; Jin JY; Wright MR; Wong H
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):421-436. PubMed ID: 38937298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
    Grinshpun A; Ren S; Graham N; DeMeo MK; Wrabel E; Carter J; Tayob N; Pereslete A; Hamilton E; Juric D; Mayer EL; Tolaney SM; Krop IE; Metzger O
    ESMO Open; 2024 Jun; 9(6):103465. PubMed ID: 38833970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
    Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
    Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
    Baird RD; van Rossum AGJ; Oliveira M; Beelen K; Gao M; Schrier M; Mandjes IAM; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; van Tinteren H; Callari M; Beddowes E; Perez-Garcia JM; Rosing H; Platte E; Nederlof P; Schot M; de Vries Schultink A; Bernards R; Saura C; Gallagher W; Cortès J; Caldas C; Linn SC
    Clin Cancer Res; 2019 Nov; 25(22):6598-6605. PubMed ID: 31439579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
    Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
    Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Taselisib in
    Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
    Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
    Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
    Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
    Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
    Langer CJ; Redman MW; Wade JL; Aggarwal C; Bradley JD; Crawford J; Stella PJ; Knapp MH; Miao J; Minichiello K; Herbst RS; Kelly K; Gandara DR; Papadimitrakopoulou VA
    J Thorac Oncol; 2019 Oct; 14(10):1839-1846. PubMed ID: 31158500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
    Kaklamani VG; Richardson AL; Arteaga CL
    Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
    Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
    Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
    Mezni E; Sabatier R; Goncalves A; Vicier C
    Bull Cancer; 2022 Feb; 109(2):216-225. PubMed ID: 35115114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.